As AI continues to entice Big Pharma, a Carlyle-led drugmaker syndicate shells out $430M for cloud computing player
The AI revolution permeating Big Pharma took a big financial step forward Wednesday, with VCs and major drugmakers coming together to acquire a cloud-focused company.
Led by the Carlyle Group, the investors will put up $430 million for a majority stake in Saama, a company that collects patient data to help speed along the drug development process. The investment arms of Pfizer, Merck, Amgen and McKesson all participated in the financing, in addition to other prominent life sciences VCs like Northpond.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.